| Name | Title | Contact Details |
|---|
Vitruvias is a specialty generic pharmaceutical business focused on the development and marketing of generic products with either (i) complex APIs that are difficult to source, or (ii) finished dosage forms that are inherently difficult to manufacture. The highly skilled team at Vitruvias has expertise in all aspects of the pharmaceutical industry, including product development, licensing, regulatory affairs, marketing, financial analysis, distribution, managed care, trade relations and sales.
Brightline is the first full-family behavioral health solution built specifically to care for kids, teens, and parents across a range of common family challenges. Launched at a time when 1 in 5 children has a behavioral health condition and up to 80% don't get the care they need, with increasing need exacerbated by the Covid-19 pandemic, Brightline is here to help families across the country thrive. With multidisciplinary care teams, personalized family system care, evidence-based care delivery, and extraordinary technology, Brightline is able to support families with whatever challenges they’re facing and ultimately help them thrive long-term. With Brightline, families can access support for a range of needs with our digital platform that includes resources and education for parents, interactive treatment exercises, and more; 1:1 coaching to support kids, teens, and parents with skill-building and guidance for dealing with tough stuff; behavior therapy, medication support, and speech therapy for a range of behavioral and developmental health needs. All right from home, right when families need it most. Join us to bring extraordinary care to families across the country!
Prospect Medical Holdings, Inc. is a leading provider of healthcare services comprised of 22 hospitals and over 140 primary and specialty care clinics located throughout Southern California, South Central Texas, Rhode Island, New Jersey, Connecticut, and Pennsylvania. Established in 1996, Prospect Medical Holdings, Inc. has grown into a significant provider of coordinated regional healthcare services throughout Southern California, South Central Texas, Rhode Island, New Jersey, Connecticut, and Pennsylvania. We were among the first healthcare providers in the country to adopt an operating model, termed Coordinated-Regional-Care, that prefigures the objectives of the Affordable Care Act – to improve quality, reduce cost and enhance overall patient care. Our comprehensive network aims to provide coordinated, personalized care. We specialize in building comprehensive networks of quality healthcare services designed to meet the needs of our patients and members. Our goal is always to ensure high-quality outcomes. Above all, we are committed to quality in all aspects of healthcare delivery, including: 1. Striving for the best possible patient outcomes 2. Maintaining the highest standards of patient safety 3. Acting with integrity at all times 4. Promoting open communication 5. Collaborating to better serve the healthcare needs of our communities
Centinel Spine is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.